Pfizer backs local Alzheimer's drug research

September 4, 2008 8:10:04 PM PDT
There was a big boost for an experimental Alzheimer's drug Thursday.

The drug, Dimebon, was originally used as an antihistamine, but early trials have shown that it may actually reverse some symptoms of Alzheimer's.

Thursday, drug giant Pfizer agreed to invest $225 million into the small San Francisco-based biotech Medivation, which owns the rights to Dimebon. The two companies will now partner on the development of the drug as they seek FDA approval.


Load Comments